Status:
COMPLETED
Acute Effects of GLP-1 on Renal Hemodynamics
Lead Sponsor:
Rigshospitalet, Denmark
Collaborating Sponsors:
Department of Cardiovascular and Renal Research, University of Southern Denmark
Conditions:
The GLP-1-mediated Gut-kidney Axis
Eligibility:
MALE
20-60 years
Phase:
NA
Brief Summary
This study investigates the hypothesis, that GLP-1's suppression of ANG II and natriuretic action increase medullary perfusion and decrease oxygen consumption, leading to higher tissue oxygenation.
Detailed Description
Human studies have recently demonstrated a significant natriuretic effect of GLP-1 when the extracellular fluid volume (ECFV) is expanded by intravenous sodium-loading; in these studies, there was a s...
Eligibility Criteria
Inclusion
- Normal health demonstrated by medical examination.
- Normal values for fasting plasma glucose, total cholesterol, triglyceride, HDL, LDL, creatinine, AST, ALT and electrolyte concentrations.
Exclusion
- Immunosuppressive treatment for the previous 12 months.
- Alcohol abuse.
- Medical treatment with oral glucocorticoids, dipeptidyl peptidase-4 (DPP-4) inhibitors, or GLP-1 receptor agonists that, in the opinion of the investigator, may interfere with glucose metabolism.
- Use of lithium.
- Medical treatment that affects insulin secretion or cardiovascular efficacy goals.
- Liver disease (ALT\> 2 x normal value).
- Renal impairment (creatinine\> 130 µM and / or albuminuria).
- Severe claustrophobia.
- MRI incompatible foreign bodies.
Key Trial Info
Start Date :
April 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2020
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT04337268
Start Date
April 1 2019
End Date
March 1 2020
Last Update
April 7 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Rigshospitalet - Glostrup
Glostrup Municipality, Copenhagen, Denmark, 2600